February 12, 2020
WPD will initiate a Phase I clinical trial for its treatment for pediatric brain cancer in Poland in collaboration with...
February 10, 2020
WPD's drug candidate was found to be potentially capable of immune reprogramming in Glioblastoma animal models.
February 5, 2020
WPD's treatment for relapsed or refractory acute myeloid leukemia has received approval from the FDA for Fast Track Designation.
January 29, 2020
WPD has confirmed the European national phase validation has been completed for the patent on antibodies against human and canine...